Early noninvasive metabolic biomarkers of mutant IDH inhibition in glioma

Marina Radoul, Donghyun Hong, Anne Marie Gillespie, Chloé Najac, Pavithra Viswanath, Russell Pieper, Joseph Costello, Hema Artee Luchman & Sabrina Ronen
Approximately 80% of low-grade glioma (LGGs) harbor mutant isocitrate dehydrogenase 1/2 (IDH1/2) driver mutations leading to accumulation of the oncometabolite 2-hydroxyglutarate (2-HG). Thus, inhibition of mutant IDH is considered a potential therapeutic target. Several mutant IDH inhibitors are currently in clinical trials, including AG-881 and BAY-1436032. However, to date, early detection of response remains a challenge. In this study we used high resolution 1H magnetic resonance spectroscopy (1H-MRS) to identify early noninvasive MR-detectable metabolic biomarkers...
1 citation reported since publication in 2021.
1 view reported since publication in 2021.

These counts follow the COUNTER Code of Practice, meaning that Internet robots and repeats within a certain time frame are excluded.
What does this mean?
1 download reported since publication in 2021.

These counts follow the COUNTER Code of Practice, meaning that Internet robots and repeats within a certain time frame are excluded.
What does this mean?